Cytovale logo

Cytovale

Emerging

Cytovale is developing a rapid point-of-care sepsis diagnostic — IntelliSep — that measures immune cell deformability via microfluidics to detect sepsis in ~8 minutes; received FDA Breakthrough Device Designation; raised $88M total;

Best for: Rapid Sepsis Diagnostic via Cell Mechanics & MicrofluidicsEmerging, rapid growth
HealthcareRapid Sepsis Diagnostic via Cell Mechanics & MicrofluidicsWebsiteUpdated May 2026

Company Overview

About Cytovale

Cytovale is a medical technology company headquartered in San Francisco, California, founded in 2014 by Lydia Sohn and others, with roots in biophysics research at the University of California, Berkeley. The company is developing the IntelliSep test — a rapid, near-patient diagnostic for sepsis that uses a proprietary microfluidic technology to measure the mechanical properties (deformability) of immune cells in whole blood. Sepsis — a life-threatening systemic immune response to infection — kills approximately 270,000 Americans annually and is the leading cause of hospital mortality, yet current diagnostic approaches (blood cultures, lactate, clinical scoring systems) are slow, non-specific, and frequently fail to identify sepsis before it progresses to organ failure and septic shock.

Business Model & Competitive Advantage

IntelliSep works by flowing a small whole blood sample through a microfluidic chip where neutrophils (key immune cells) are squeezed through defined constrictions. Sepsis causes measurable changes in neutrophil cell mechanics — septic neutrophils become more deformable (softer) than healthy neutrophils due to cytoskeletal changes driven by sepsis pathophysiology. Cytovale's system measures these biophysical changes to generate an IntelliSep Index score within approximately 8 minutes at the point of care, providing emergency physicians with an objective sepsis likelihood score to guide early treatment decisions. The test has received FDA Breakthrough Device Designation, reflecting the agency's assessment that it addresses an unmet medical need.

Competitive Landscape 2025–2026

Cytovale raised $88M in total funding across multiple rounds, with investors including Khosla Ventures, Greycroft, Triventures, and other healthcare and life sciences investors. The company competes in the sepsis diagnostics market against Inflammatix (host-gene expression sepsis test), BioMérieux (blood culture and procalcitonin testing), and clinical AI decision support tools. Cytovale's differentiation is the speed (8-minute turnaround versus 24–72 hours for blood culture), the non-culture-based mechanism, and the point-of-care deployment model suitable for emergency department workflows.

Founded
2014
Headquarters
San Francisco, California
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Cytovale is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Similar Brands

Oracle Health logo

Oracle Health

Healthcare
HealthtechNorth AmericaB2b

Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve

athenahealth logo

athenahealth

Healthcare
B2bCloud NativeEnterpriseErpHealthtechNorth AmericaSaas

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on

CoverMyMeds logo

CoverMyMeds

Healthcare Revenue Cycle & Health IT
HealthtechB2bPlatformEnterpriseServicesTechnologyAutomationAnalytics

CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline t

Abridge logo

Abridge

Healthcare
HealthtechB2bUnicornAi PoweredNorth America

Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led b

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

Compare Cytovale with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Cytovale

Claim This Profile

Are you from Cytovale? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Cytovale Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cytovale vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →